AXSM Q2 2026: Revenue Jumps 46% but SG&A Surge to $208M Widens Net Loss

Axsome Therapeutics (NASDAQ: AXSM) posted Q2 2026 net product revenue of $218.4 million, a 45.6% year-over-year increase from $150.0 million, but a 59.7% surge in selling, general, and administrative expenses widened the company's net loss despite the top-line growth. GAAP EPS came in at -$0.99, missing the -$0.86 analyst consensus by 15.1%, while the net loss expanded to $51.3 million from $48.0 million in the year-ago quarter.

Q2 2026 Results

• Total net product revenue: $218.4 million, up 45.6% year-over-year from $150.0 million in Q2 2025
• AUVELITY net product sales: $180.3 million, up 51% year-over-year from $119.6 million, with approximately 266,000 total prescriptions written in the quarter, representing a 34% year-over-year increase
• SUNOSI net product revenue: $35.8 million, up 20% year-over-year from $30.0 million
• SYMBRAVO net product sales: $2.3 million, up 461% year-over-year from $0.4 million following its June 2025 launch
• Cash and equivalents: $319.9 million at June 30, 2026, compared to $322.9 million at December 31, 2025

What Drove the Results

GAAP EPS of -$0.99 missed the -$0.86 consensus estimate by 15.1%, and revenue of $218.4 million came in without a disclosed consensus figure for direct comparison. The central driver of the widening loss was SG&A expenses, which rose 59.7% year-over-year to $208.1 million from $130.3 million in Q2 2025. According to the company's press release, the increase reflects commercialization activities for AUVELITY, including a sales force expansion and launch activities for the new Alzheimer's disease agitation indication, as well as commercialization costs for SYMBRAVO.

R&D expenses declined modestly to $46.2 million from $49.5 million in Q2 2025, with the company citing lower costs for the AXS-05 and AXS-14 programs. Total cost of revenue was essentially flat at $13.6 million versus $13.4 million in the prior-year period. The Q2 2026 net loss of $51.3 million included $27.1 million in stock-based compensation expense, which represents a material non-cash charge embedded in the GAAP result.

On the commercial side, AUVELITY new-to-brand prescriptions among patients aged 65 and older increased 126% in the first eight weeks following the June 2026 Alzheimer's disease agitation launch compared to the same period in the prior quarter. Overall new-to-brand prescriptions in Q2 2026 rose 26% compared to Q1 2026. The company also reported that payer coverage for AUVELITY stands at approximately 89% of all lives covered.

Wall Street View

Three analyst firms updated their views on AXSM following the Q2 report. Morgan Stanley analyst Sean Laaman maintained an Equal-Weight rating and raised his price target from $242 to $251. Guggenheim analyst Yatin Suneja maintained a Buy rating and raised his target from $260 to $275. RBC Capital analyst Leonid Timashev maintained an Outperform rating but lowered his price target from $304 to $297. Shares fell -2.32% on Tuesday, August 11, 2026, while the S&P 500 declined 0.32%.

Investor Takeaway

Axsome's Q2 results illustrate the tension between accelerating product adoption and the near-term cost of building the commercial infrastructure to sustain it: AUVELITY's Alzheimer's agitation launch is generating early prescription momentum, but SG&A expenses now exceed quarterly revenue by approximately $208 million against $218 million in sales, leaving the path to cash flow positivity dependent on whether prescription volume scales faster than the elevated cost base. The company's stated guidance that current cash is sufficient to fund operations into cash flow positivity, combined with anticipated pipeline catalysts including Phase 3 ENGAGE topline data in binge eating disorder in Q4 2026 and the AXS-12 narcolepsy PDUFA date of May 1, 2027, gives investors concrete near-term milestones to evaluate that trajectory.